Stephen Bright
Senior Lecturer of Addiction at Edith Cowan University
Data updated
Research Footprint
Stephen Bright appears in 5 tracked papers (2020–2023), most studied alongside MDMA, across Anxiety Disorders, Depressive Disorders and Microdosing.
Most-cited paper: Presence, Trust, and Empathy: Preferred Characteristics of Psychedelic Carers (26 citations).
Frequent co-authors: Vince Polito.
Background & Research
Dr Stephen Bright is a psychologist and Senior Lecturer of Addiction at Edith Cowan University in Australia. His research and public advocacy focus on alcohol and other drugs, harm reduction, psychedelic-assisted psychotherapy, and the emerging science of microdosing. He has also been involved in founding and supporting psychedelic research initiatives in Australia.
Key Impact
He is a notable Australian psychedelic-science researcher whose work spans microdosing, psychedelic-assisted psychotherapy, and the therapeutic conduct of psychedelic care.
Collaboration Network
1 collaborator· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Stephen Bright is associated with.
Edith Cowan University
Edith Cowan University (ECU) is a public research university based in Western Australia, Australia, with campuses in Perth and regional centres. Established as a university in 1991, it offers undergraduate and postgraduate programs across a range of disciplines and engages in research.
View stakeholder →Psychedelic Research in Science & Medicine (PRISM)
Psychedelic Research in Science & Medicine (PRISM) is an Australian nonprofit research charity based in Melbourne, with activity and collaborators across Australia and internationally. It was established in 2011 to initiate, coordinate, and support formal research into medicinal psychedelics and related technologies. PRISM says it serves researchers, clinicians, and the wider psychedelic science community through scientific expertise, education, and consultation. PRISM’s public role is centered on evidence-based psychedelic science, knowledge translation, and policy-facing advocacy rather than direct patient services. Its website describes a research network that connects academics, clinicians, and students to coordinate study proposals, collaborations, funding opportunities, and peer-to-peer education. Documented current initiatives include a Psychedelic Research Network and support for Australian clinical research, including work related to psilocybin, MDMA, and virtual reality tools for preparation and integration.
View stakeholder →